Abstracts Archive - Page 2324 of 2607 - ACR Meeting Abstracts

Abstract Number: 1631 • 2013 ACR/ARHP Annual Meeting
Transcription Activation-Like Effector Nuclease-Mediated Enhancer Knockout Influences TNFAIP3 Gene Expression and Mimics a Functional Phenotype Associated With Systemic Lupus Erythematosus
Shaofeng Wang¹, Feng Wen², Bo He³ and Patrick M. Gaffney⁴, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Emerging technologies for precise, targeted genome editing provide new opportunities for the functional elucidation of causal genetic variants and genomic elements without the confounding…
Abstract Number: 1632 • 2013 ACR/ARHP Annual Meeting
Identification Of a Novel Systemic Lupus Erythematosus Risk Locus Between FCHSD2 and P2RY2 In Koreans
Christopher J. Lessard^1,2, Satria Sajuthi³, So-Young Bang⁴, Hye-Soon Lee⁵, Young Mo Kang⁶, Chang-Hee Suh⁷, Won Tae Chung⁸, Soo-Kon Lee⁹, Jung-Yoon Choe¹⁰, Seung-Cheol Shim¹¹, Shin-Seok Lee¹², Ji Hee Oh¹³, Young Jin Kim¹⁴, Jong-Young Lee¹⁴, Bok-Ghee Han¹⁴, Patrick M. Gaffney¹⁵, Timothy J. Vyse for SLEGEN¹⁶, John B. Harley^17,18, Carl D. Langefeld³, Sang-Cheol Bae¹⁹, Kathy L. Sivils^1,2 and Betty P. Tsao²⁰, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ⁴Hanyang University Guri Hospital, Guri, South Korea, ⁵Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ⁶Department of Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea, ⁷Department of Rheumatology, Ajou University Hospital, Suwon, South Korea, ⁸Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital, Busan, South Korea, ⁹Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ¹⁰Catholic University of Daegu School of Medicine, Daegu, South Korea, ¹¹Division of Rheumatology, Daejeon Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Daejeon, South Korea, ¹²Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ¹³Division of Structural and Functional Genomics, Center for Genome Science, Korea National Institute of Health, Osong, South Korea, ¹⁴Korea National Institute of Health, Osong, South Korea, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶King's College London, Guy's Hospital, London, United Kingdom, ¹⁷Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁸US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹⁹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²⁰Division of Rheumatology, Department of Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, heterogeneous autoimmune disorder characterized by inflammation, loss of tolerance to self-antigens, and dysregulated interferon responses. Although >40…
Abstract Number: 1633 • 2013 ACR/ARHP Annual Meeting
Sub-Phenotype Mapping In Systemic Lupus Erythematosus Identifies Multiple Novel Loci Associated With Circulating Interferon Alpha
Silvia Kariuki¹, Yogita Ghodke², Jessica M. Dorschner², Beverly Chrabot³, Jennifer A. Kelly⁴, Betty P. Tsao⁵, Robert P. Kimberly⁶, Marta E. Alarcon-Riquelme⁷, Chaim O. Jacob⁸, Lindsey A. Criswell⁹, Kathy L. Sivils¹⁰, Carl D. Langefeld¹¹, John B. Harley¹², Andrew D. Skol¹ and Timothy B. Niewold², ¹Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ²Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Division of Rheumatology, Department of Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ⁶Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK, ⁸Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ⁹Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ¹⁰Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ¹²Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a phenotypically heterogeneous complex disease. Our previous work has documented significant genetic heterogeneity, with some well-validated risk factors demonstrating…
Abstract Number: 1634 • 2013 ACR/ARHP Annual Meeting
Genome-Wide Transcriptional Profiling Of Isolated Immune Cell Populations From SLE Patients With Different Ancestral Backgrounds
Shruti Sharma¹, Zhongbo Jin², Elizabeth Rosenzweig³, Swapna Rao⁴, Kichul Ko⁴ and Timothy B. Niewold², ¹Gwen Knapp Center for Lupus Research, University of Chicago, Chicago, IL, ²Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ⁴Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex multi-system autoimmune disease of uncertain etiology. Different ancestral backgrounds demonstrate different clinical manifestations and autoantibody profiles. Whole…
Abstract Number: 1635 • 2013 ACR/ARHP Annual Meeting
Identification Of Novel Genetic Associations Within Major Histocompatibility Complex (MHC) Class I and Class II In Systemic Lupus Erythematosus (SLE) Patients: An Examination Of Epitopes Of Early Autoimmunity
Gerard Dumancas¹, Chee Paul Lin², Indra Adrianto¹, Jennifer A. Kelly¹, Stuart B. Glenn¹, Jourdan Anderson², John B. Harley^3,4, Timothy J. Vyse⁵, Robert P. Kimberly⁶, Marta E. Alarcon-Riquelme⁷, Carl D. Langefeld⁸, Betty P. Tsao⁹, Lindsey A. Criswell¹⁰, Chaim O. Jacob¹¹, Patrick M. Gaffney¹², Kathy Sivils¹², Judith A. James^12,13 and Courtney Montgomery², ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁵Medical & Molecular Genetics, King's College London, London, United Kingdom, ⁶Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK, ⁸Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ⁹Division of Rheumatology, Department of Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ¹⁰Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ¹¹Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ¹²Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹³College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibody production, multiple organ involvement, strong genetic predisposition and specifically, to be associated with…
Abstract Number: 1636 • 2013 ACR/ARHP Annual Meeting
Pro-Inflammatory HDL and Subclinical Atherosclerosis Are Associated With Altered Expression Of Epigenetic and Oxidative Stress-Related Gene Transcripts In SLE
Brian Skaggs¹, Bevra H. Hahn², Jennifer M. Grossman³, Elaine Lourenco¹, Isao Matsuura⁴, Lori Sahakian⁵ and Maureen A. McMahon⁶, ¹Medicine/Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ³Division of Rheumatology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁴UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵Division of Rheumatology, Department of Medicine,, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁶Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Premature atherosclerosis is widely recognized as a significant co-morbid condition of systemic lupus erythematosus (SLE), but exact mechanisms are unknown. Although traditional cardiovascular risk…
Abstract Number: 1637 • 2013 ACR/ARHP Annual Meeting
IKZF1 Modulates PP2Ac Expression Through An Intronic Binding Site
Kamalpreet Nagpal¹, Katsue S. Watanabe² and George C. Tsokos³, ¹Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
IKZF1 modulates PP2Ac expression through an intronic binding siteKamalpreet Nagpal1, Katsue Sunahori2, George C. Tsokos11Department of Medicine, Division of Rheumatology, Beth Israel Deaconess Medical Center,…
Abstract Number: 1638 • 2013 ACR/ARHP Annual Meeting
Concurrent Autoimmune Disease and Autoantibodies In a Large, Multi-Racial Cohort Of First Degree Blood Relatives Of SLE Patients
Julie M. Robertson¹, Benjamin F. Bruner², Rufei Lu¹, Joel M. Guthridge¹, John B. Harley³ and Judith A. James⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Harding University, Searcy, AR, ³Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: First degree relatives (FDRs) of SLE patients have an increased risk of developing autoantibodies and/or autoimmune disorders. Between 20% and 40% of FDRs develop…
Abstract Number: 1639 • 2013 ACR/ARHP Annual Meeting
GWAS In Hispanic and Latin American Individuals Enriched For Amerindian Ancestry Identifies a New Locus Associated With Systemic Lupus Erythematosus
Marta Eugenia Alarcon Riquelme¹, Julie T. Ziegler², Mary E. Comeau³, Elena Sanchez⁴, Bernado Pons-Estel⁵, Eduardo Acevedo⁶, Jorge Mariano Cucho⁶, Ignacio Garcia de la Torre⁷, Mario H. Cardiel⁸, Pedro Miranda⁹, Luis Cattogio¹⁰, Marco Maradiaga¹¹, Jorge Esquivel-Valerio¹², Jose F Moctezuma¹³, Mercedes Garcia¹⁴, Guillermo Berbotto¹⁵, Alejandra Babini¹⁶, Hugo Scherbarth¹⁷, Sergio Toloza¹⁸, Judith A James¹⁹, Teresa Tusie-Luna²⁰, John B Harley²¹, Raphael Zidovetski²², Carl Langefeldt² and Chaim O. Jacob²³, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Wake Forest School of Medicine, Winston-Salem, NC, ³Wake Forest University Health Sciences, Winston-Salem, NC, ⁴King's College London, London, United Kingdom, ⁵Hospital Provincial de Rosario, Rosario, Argentina, ⁶Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, ⁷Hospital General de Occidente, Zapopan, Mexico, ⁸Centro de Investigacion Clinica de Morelia, Morelia, Mexico, ⁹Universidad de Chile and Centro de Estudios Reumatologicos, Santiago de Chile, Chile, ¹⁰Hospital Italiano, Buenos Aires, Argentina, ¹¹Hospital General de Culiacán, Culiacan, Sinaloa, Mexico, ¹²Hospital Universitario Dr. José Eleuterio González, Universidad Autonoma de Nuevo León, Nuevo Leon, Mexico, ¹³Hospital General de Mexico, Mexico, Mexico, ¹⁴Hospital San Martin, La Plata, Argentina, ¹⁵Hospital Eva Peron, Granadero Baigorria, Argentina, ¹⁶Hospital Privado de Cordoba, Cordoba, Argentina, ¹⁷H.I.G.A. Oscar E. Alende, Mar del Plata, Argentina, ¹⁸Hospital San Juan Bautista, Catamarca, Argentina, ¹⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²⁰Instituto de Investigaciones Biomédicas de la Universidad Nacional Autónoma de México, and Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ²¹Childrens Hospital, Cincinnati, OH, ²²University of Southern California, Los Angeles, CA, ²³Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: Systemic lupus erythematosus (SLE), a chronic autoimmune disease with a strong genetic component, exhibits a 9:1 female to male ratio and disproportionate impact on…
Abstract Number: 1640 • 2013 ACR/ARHP Annual Meeting
Methotrexate Treatment Affects Effector, But Not Regulatory T Cells in Juvenile Idiopathic Arthritis
Maja Bulatovic Calasan¹, S.J. Vastert², Rianne C. Scholman³, Frederik Verweij³, Mark Klein³, Nico M. Wulffraat⁴, Berent J. Prakken³ and Femke van Wijk³, ¹Paediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ²Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ³University Medical Center Utrecht, Utrecht, Netherlands, ⁴Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: The balance between regulatory (Treg) and effector T cells (Teff) is crucial for immune regulation in juvenile idiopathic arthritis (JIA). How methotrexate (MTX), the…
Abstract Number: 1641 • 2013 ACR/ARHP Annual Meeting
Bispecific Antibodies For Redirection Of Human Regulatory T Cells To Surface-Inducible Autoantigen La/SS-B
Stefanie Koristka¹, Marc Cartellieri², Claudia Arndt², Anja Feldmann², Irene Michalk², Claudia C. Bippes², Nicole Berndt², Anne Hermsdorf², Slava Stamova², Biji T. Kurien³, Robert Hal Scofield⁴, A. Darise Farris⁵, Judith A. James⁶, Holger Bartsch⁷ and Michael Bachmann², ¹Carl Gustav Carus TU-Dresden, Dresden, Germany, ²Inst. Immunology, Carl Gustav Carus TU-Dresden, Dresden, Germany, ³College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ⁵Arthritis & Immunology Program, Oklahoma Medical Research Foun, Oklahoma City, OK, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Inst. Immunol., Carl Gustav Carus TU-Dresden, Dresden, Germany
Background/Purpose: Adoptive transfer of regulatory T cells (Tregs) represents a promising strategy for treatment of auto- and alloimmunity. However, it is difficult to obtain therapeutically…
Abstract Number: 1642 • 2013 ACR/ARHP Annual Meeting
CD25+CD39+ Regulatory T Cells Are Enriched At The Site Of Inflammation Of Patients With Rheumatoid Arthritis and Impaired In Suppressing IL-17A Secretion
Jessica Herrath¹, Karine Chemin², Inka Albrecht¹, Anca Catrina² and Vivianne Malmström³, ¹Department of Medicine, Solna, Unit of Rheumatology, Karolinska University Hospital, Department of Medicine, Solna, Unit of Rheumatology, Stockholm, Sweden, ²Department of Medicine, Solna, Unit of Rheumatology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Regulatory T cells (Tregs) are important for the maintenance of self-tolerance and are implicated in the origin of autoimmunity. Despite enrichment of Tregs in…
Abstract Number: 1603 • 2013 ACR/ARHP Annual Meeting
Sustained Reductions In Circulating B Cell Populations and Immunoglobulin G Levels With Long-Term Belimumab Treatment In Patients With Systemic Lupus Erythematosus
Herbert Struemper¹, William Freimuth², Christi Kleoudis³, Thi-Sau Migone⁴, David Roth³ and William Stohl⁵, ¹GlaxoSmithKline, Research Triangle Park, NC, ²Human Genome Sciences, Inc., Rockville, MD, ³GlaxoSmithKline, King of Prussia, PA, ⁴Igenica, Burlingame, CA, ⁵Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: Belimumab treatment in autoantibody-positive systemic lupus erythematosus (SLE) patients for up to 76 weeks results in sustained reduction in several circulating B cell subsets,…
Abstract Number: 1604 • 2013 ACR/ARHP Annual Meeting
Effects Of Chronic Treatment With Blisibimod, An Inhibitor Of B Cell Activating Factor, On Renal and Inflammation Biomarkers In Patients With Systemic Lupus Erythematosus: Observations From The Placebo-Controlled Pearl-SC and Open-Label Extension Studies
Richard A. Furie¹, Matthew Thomas², Alvina Chu³, Renee S. Martin³, Colin Hislop³ and Morton A. Scheinberg⁴, ¹The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, ²Health and Research Centre, Trivandrum, Kerala, India, ³Anthera Pharmaceuticals Inc, Hayward, CA, ⁴Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo, Brazil
Background/Purpose: To evaluate the effects of subcutaneously-administered blisibimod on renal and inflammation biomarkers in patients with SLE during the phase 2b clinical trial PEARL-SC (NCT01162681)…
Abstract Number: 1605 • 2013 ACR/ARHP Annual Meeting
Post-Marketing Experience With Belimumab In U.S. Lupus Centers: Data From The Lupus Clinical Trials Consortium, Inc. (LCTC) National Patient Registry
Jinoos Yazdany¹, Doruk Erkan², Jorge sanchez-Guerrero³, Bevra H. Hahn⁴, Alana B. Levine², Galina Marder⁵, W. Joseph McCune⁶ and Ellen M. Ginzler⁷, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada, ⁴Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵Medicine, North Shore Long Island Health System, Great Neck, NY, ⁶Int Med/ Rheum, University of Michigan, Ann Arbor, MI, ⁷Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY
Background/Purpose: Much of the published experience with belimumab in lupus patients has derived from clinical trials. We examined the non-sponsored experience with belimumab in routine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].